Arcutis to Present at Upcoming Investor Conferences
Rhea-AI Summary
Arcutis (Nasdaq: ARQT) said company management will participate in two investor conferences in November 2025. The company will appear at Guggenheim’s 2nd Annual Healthcare Innovation Conference with a fireside chat on Tuesday, November 11, 2025 at 8:30 am ET, and at the TD Cowen Immunology & Inflammation Summit with a fireside chat on Wednesday, November 12, 2025 at 9:00 am ET.
Webcasts for both events can be accessed in the Events section of the company website, and replays will be available for 180 days after each conference.
Positive
- None.
Negative
- None.
News Market Reaction 52 Alerts
On the day this news was published, ARQT declined 2.34%, reflecting a moderate negative market reaction. Argus tracked a peak move of +25.7% during that session. Our momentum scanner triggered 52 alerts that day, indicating high trading interest and price volatility. This price movement removed approximately $74M from the company's valuation, bringing the market cap to $3.09B at that time. Trading volume was very high at 4.5x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
WESTLAKE VILLAGE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in two upcoming investor conferences. Details for the company’s participation are as follows:
Guggenheim’s 2nd Annual Healthcare Innovation Conference, November 10-12, 2025
Fireside Chat Date: Tuesday, November 11, 2025
Fireside Chat Time: 8:30 am ET
TD Cowen Immunology & Inflammation Summit, November 12-13, 2025
Fireside Chat Date: Wednesday, November 12, 2025
Fireside Chat Time: 9:00 am ET
Webcasts for these conferences may be accessed at the “Events” section of the Company’s website. A replay of these webcasts will be available on the Arcutis website for 180 days following the conference.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf
ir@arcutis.com
FAQ
When will Arcutis (ARQT) present at Guggenheim’s 2nd Annual Healthcare Innovation Conference?
What time is Arcutis (ARQT) scheduled to speak at the TD Cowen Immunology & Inflammation Summit?
How can investors watch Arcutis (ARQT) webcasts for the November 2025 conferences?
How long will the Arcutis (ARQT) conference replay be available after the events?
Will Arcutis (ARQT) publish presentation slides or materials for the November 2025 fireside chats?
Who from Arcutis (ARQT) will participate in the November 2025 investor conferences?
